Virtu Financial LLC Purchases New Shares in LAVA Therapeutics (NASDAQ:LVTX)

Virtu Financial LLC acquired a new position in LAVA Therapeutics (NASDAQ:LVTX) during the third quarter, Holdings Channel.com reports. The firm acquired 19,103 shares of the company’s stock, valued at approximately $32,000.

Separately, Pathway Financial Advisors LLC lifted its stake in shares of LAVA Therapeutics by 70.8% in the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after acquiring an additional 42,500 shares in the last quarter.

LAVA Therapeutics Price Performance

LAVA Therapeutics stock opened at $1.03 on Friday. LAVA Therapeutics has a 12 month low of $0.96 and a 12 month high of $6.47. The company has a fifty day moving average price of $1.62 and a two-hundred day moving average price of $1.78. The company has a market cap of $26.11 million, a PE ratio of -1.00 and a beta of 0.43.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LVTX shares. JMP Securities restated a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Leerink Partners restated a “market perform” rating and issued a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. HC Wainwright dropped their target price on shares of LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research report on Friday. Finally, Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, LAVA Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.33.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.